Zoledronic acid-associated thrombotic thrombocytopenic purpura.
G. Ferretti,M. Petti,P. Carlini,M. Zeuli,Alessandra Picardi,Giovanna Meloni,E. Bria,P. Papaldo,A. Fabi,F. Cognetti
DOI: https://doi.org/10.1093/ANNONC/MDH478
IF: 51.769
2004-12-01
Annals of Oncology
Abstract:Although many cases are idiopathic, thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS) sometimes occurs in association with cancer, drugs (cyclosporine A, mitomycin, quinine, ticlopidine, clopidogrel), pregnancy, autoimmune diseases, infection and bone marrow transplantation [1]. This clinical heterogeneity poses a challenge to understanding the pathogenesis of TTP and selecting appropriate therapies. We report data on a 52-year-old woman who was admitted to our hospital after suffering progressive neurological derangement for several days. These symptoms had been increasing and the patient had become confused and somnolent soon after receiving the third zoledronic acid infusion. Two years before, she had undergone right mastectomy, adjuvant anthracycline-based chemotherapy and endocrine therapy (tamoxifen) for breast cancer. Bone relapse (lumbar and sacral vertebrae and pelvis with both femurs) had recently been diagnosed and she had received palliative radiotherapy, further endocrine therapy (letrozole) and the first infusion of zoledronate. At admission she appeared confused with absence of responsiveness to external stimuli. Transdermal fentanyl used for pain relief was stopped. Laboratory analysis showed severe hypercalcemia with anemia and thrombocytopenia. Reticulocyte count was 6.33% (range 0.60–2.60), lactate dehydrogenase 685 U/l (range 220–480) and bilirubin 1.58 mg/dl (range 0.10–1.10). Fragmented red blood cells were rare. The coagulation tests were close to normality. Her renal function was impaired (creatinine clearance 46 ml/min, range 70–140). This constellation suggested acquired TTP. After correcting hypercalcemia by fluid infusion, diuretics and zoledronate, she remained confused and somnolent. After plasma exchange therapy, her platelet count increased and the neurological disturbances ceased. Considering the resistance to endocrine therapy and the possible paraneoplastic origin of TTP, she was given first-line chemotherapy for metastatic disease (paclitaxel 175 mg/m). Although the patient received further plasma exchange therapy, she experienced a fatal TTP relapse 20 days after her admission. Neither autopsy nor other postmortem evaluations were performed. With the marketed use of zoledronic acid, renal deterioration progressing to renal failure and dialysis has been reported [2]. Acute tubular necrosis has been described as a potential mechanism associated with zoledronic acid. Thus, similar to mitomycin C or cyclosporin [1], the acute vascular changes described as thrombotic microangiopathy resembling TTP-HUS could be caused by a toxic effect of the drug on renal vascular endothelium. However, in our patient the sudden TTP onset could suggest an immune-mediated reaction associated with zoledronate, as previously described for quinine, ticlopidine and clopdidogrel [1]. Activity of ADAMTS13, a member of a disintegrin and metalloprotease with thrombospondin type 1 motifs family of metalloproteases, might be inhibited by antibodies that prevent enzyme binding to endothelial cell surfaces or block interactions with cellular or plasmatic modulators or reduce the absolute amount of circulating ADAMTS13 in the plasma [3, 4]. Moreover, Boissier et al. [5] demonstrated that zoledronate is the most potent bisphosphonate in inhibiting the proteolytic activity of metalloproteases. Because of the serious nature of the reported events, health care professionals should accurately monitor renal function before administering zoledronic acid to their patients [2]. A better understanding of the clinical importance of drug-associated TTP-HUS will require a systematic review of published case reports using explicit criteria for establishing a cause– effect relationship.